Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients

Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients

Posted by Adam Awdish on

Pooled Human AB Serum Plasma Derived from Innovative Research was used in the following study:

 

Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B-cell Malignancy Patients

Michael Maschan, Paolo F. Caimi, Jane Reese-Koc, Gabriela Pacheco Sanchez, Ashish A. Sharma, Olga Molostova, Larisa Shelikhova, Dmitriy Pershin, Alexey Stepanov, Yakov Muzalevskii, Vinicius G. Suzart, Folashade Otegbeye, David Wald, Ying Xiong, Darong Wu, Adam Knight, Ibe Oparaocha, Beatrix Ferencz, Andre Roy, Andrew Worden, Winfried Kruger, Michael Kadan, Dina Schneider, Rimas Orentas, Rafick-Pierre Sekaly, Marcos de Lima & Boro Dropulić

Nature Communications
December 10, 2021

Pediatric B-acute lymphoblastic leukemia (B-ALL) is typically a highly curable disease, however, about 3% of patients will suffer from refractory disease and up to 15% of patients can relapse after treatment with chemotherapy. Normal treatment for Non-Hodgkin’s lymphoma (NHL) involves combination chemotherapy treatment, and treatments are generally successful.

One specific 95 kDa glycoprotein found on the surfaces of B-cells expressed by most B-cell malignancies, including NHL and B-ALL, is CD19. Immunotherapies that target CD19, namely those utilizing Chimeric antigen receptor (CAR) T cells, have been shown to be effective in treating patients with B-cell malignancies. The ability to manufacture CAR T cells at the place-of-care would be beneficial as it would diminish the cost and time associated with the need to cryopreserve and transport cells from satellite facilities, improving the performance and accessibility of treatment for B-cell malignancies.

Researchers in this study developed place-of-care anti-CD19 CAR (CAR19) T cells made of 4-1BB co-stimulatory and TNFRSF19 transmembrane domains which demonstrated anti-tumor properties. Testing showed this treatment induced Complete Remission rates of 89% of B-ALL and 73% for NHL.

 

Related products available from Innovative Research also include:

Pooled Human Urine

Single Donor Human Saliva

Pooled Human Plasma Apheresis Derived

  • Tags: Human Serum, Pooled Human AB Serum Plasma Derived

    • The next big thing: it's what you do. The biological research materials you need to discover it? That's what we do! We love seeing how our products are being used in real-life applications and contributing to scientific acheivements every day. With thousands of published references and decades of proven results, you can count on us to help you source the high-quality biomaterials you need that will deliver reliable, consistent results - kit to kit, lot to lot, all study long. So what are you waiting for? All great discoveries start somewhere... yours starts with Innovative Research! Get in touch with our team today!


    Related Posts

    Detection of SARS-CoV-2 RNA through Tandem Isothermal Gene Amplification without Reverse Transcription
    Pooled Human Plasma (Blood Derived) from Innovative Research was used in the following ...
    Read the Article
    Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis
    Pooled Human Serum Off The Clot from Innovative Research was used in the following stud...
    Read the Article
    PD-LAMP Smartphone Detection of SARS-CoV-2 on Chip
    Pooled Human Saliva from Innovative Research was used in the following study:   PD-LAM...
    Read the Article

    ← Older Post Newer Post →

    ×